Search Results

By GARTH W. STROHBEHN, MD, MPhil; ALLEN S. LICHTER, MD, FASCO; AND MARK J. RATAIN, MD, FASCO  / September 25, 2026

Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors

The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small...